FDA PMA FDA Class 3 Approved 🇺🇸 United States

Aortic Valve, Prosthesis, Percutaneously Delivered

PMA: P100041 · Supplement: S039 · Decision Sep 23, 2013
Classifications
1
FEI Numbers
24
Registration Numbers
24

Basic Information

Device Name
Aortic Valve, Prosthesis, Percutaneously Delivered
Trade Name
EDWARDS SAPIEN TRANSCATHETER HEART VALVE AND TRANSFEMORAL ACCESSORIES
PMA Number
P100041
Supplement Number
S039
Device Class
FDA Class 3
Product Code
NPT
Generic Name
Aortic valve, prosthesis, percutaneously delivered
Medical Specialty
Unknown
Advisory Committee
Cardiovascular
Decision
Approved
Decision Code
APPR
Decision Date
September 23, 2013
Date Received
August 28, 2013
Supplement Type
Normal 180 Day Track
Supplement Reason
Labeling Change - Indications/instructions/shelf life/tradename
Expedited Review
N

Advisory Committee Statement

APPROVAL FOR REMOVAL OF ACCESS APPROACH FROM DEVICE LABELING. THE DEVICE IS INDICATED FOR PATIENTS WITH SEVERE SYMPTOMATIC CALCIFIED NATIVE AORTIC VALVE STENOSIS WITHOUT SEVERE AORTIC INSUFFICIENCY AND WITH EJECTION FRACTION > 20% WHO HAVE BEEN EXAMINED BY A HEART TEAM INCLUDING AN EXPERIENCED CARDIAC SURGEON AND A CARDIOLOGIST AND FOUND TO BE: 1) INOPERABLE AND IN WHOM EXISTING CO-MORBIDITIES WOULD NOT PRECLUDE THE EXPECTED BENEFIT FROM CORRECTION OF THE AORTIC STENOSIS; OR 2) BE OPERATIVE CANDIDATES FOR AORTIC VALVE REPLACEMENT BUT WHO HAVE A PREDICTED OPERATIVE RISK SCORE >= 8% OR ARE JUDGED BY THE HEART TEAM TO BE AT A >= 15% RISK OF MORTALITY FOR SURGICAL AORTIC VALVE REPLACEMENT.

Classifications

This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.

Product Code Device Name
NPT Aortic Valve, Prosthesis, Percutaneously Delivered